# US 2013/0157354 A1 · Transgenic non-human animals for producing chimeric antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157354 A1
- Document ID: US20130157354A1
- Status: Published application
- Kind: A1
- Application number: 13/597,788
- Filed: 2012-08-29
- Published: 2013-06-20
- Earliest claimed: 1994-03-09
- Assignees: Genpharm Internationl
- Inventors: Nils Lonberg; Robert M. Kay
- Web page: https://patentgrep.com/patent/US20130157354A1

## CPC

- C07K 16/462: {Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A01K 67/0276: Knock-out vertebrates
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/105: Murine
- A01K 2267/01: Animal expressing industrially exogenous proteins
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.

## Claims

### Claim 1

A method for constructing a nucleic acid molecule encoding a human heavy chain immunoglobulin, which method comprises operably linking a nucleic acid molecule encoding a human heavy chain variable region to a nucleic acid molecule encoding a human heavy chain constant region, wherein the human heavy chain variable region is isolated from a B lymphocyte from a transgenic mouse, wherein the genome of said transgenic mouse comprises inactivated murine variable regions and an unrearranged human heavy chain immunoglobulin variable region operably linked to a mu constant region gene segment, wherein the unrearranged heavy chain variable region comprises multiple human VH gene segments, multiple human D gene segments, and multiple human JH gene segments, and wherein the mu constant region is selected from the group consisting of:
(a) a human S-mu sequence and a human or mouse mu coding sequence; and
(b) a mouse S-mu sequence and a human or mouse mu coding sequence.

### Claim 2 (depends on 1)

The method of claim 1 wherein the nucleic acid molecule encoding a human heavy chain immunoglobulin is operably linked to an expression vector.

### Claim 3 (depends on 2)

The method of claim 2 wherein the expression vector comprising the nucleic acid molecule encoding a human heavy chain immunoglobulin is introduced into a host cell.

### Claim 4 (depends on 3)

The method of claim 3 wherein the host cell is a mammalian cell.

### Claim 5 (depends on 4)

The method of claim 4 wherein the mammalian host cell is selected from the group consisting of a CHO cell, a SP20 cell, and a NS0 cell.

### Claim 6 (depends on 1)

The method of claim 1 wherein the human heavy chain immunoglobulin is an IgG, IgA, or IgE isotype.
